Barbara Murdoch
University of Toronto
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Barbara Murdoch.
Nature Medicine | 1998
Mickie Bhatia; Dominique Bonnet; Barbara Murdoch; Olga I. Gan; John E. Dick
The detection of primitive hematopoietic cells based on repopulation of immune-deficient mice is a powerful tool to characterize the human stem-cell compartment. Here, we identify a newly discovered human repopulating cell, distinct from previously identified repopulating cells, that initiates multilineage hematopoiesis in NOD/SCID mice. We call such cells CD34neg-SCID repopulating cells, or CD34neg-SRC. CD34neg-SRC are restricted to a Lin–CD34–CD38– population without detectable surface markers for multiple lineages and CD38 or those previously associated with stem cells (HLA-DR, Thy-1 and CD34). In contrast to CD34+ subfractions, Lin–CD34–CD38– cells have low clonogenicity in short-and long-term in vitro assays. The number of CD34neg-SRC increased in short-term suspension cultures in conditions that did not maintain SRC derived from CD34+ populations, providing independent biological evidence of their distinctiveness. The identification of this newly discovered cell demonstrates complexity of the organization of the human stem-cell compartment and has important implications for clinical applications involving stem-cell transplantation.
Proceedings of the National Academy of Sciences of the United States of America | 2003
Barbara Murdoch; Kristin Chadwick; Matthew Martin; Farbod Shojaei; Kavita Shah; Lisa Gallacher; Randall T. Moon; Mickie Bhatia
Human hematopoietic stem cells are defined by their ability to repopulate multiple hematopoietic lineages in the bone marrow of transplanted recipients and therefore are functionally distinct from hematopoietic progenitors detected in vitro. Although factors capable of regulating progenitors are well established, in vivo regulators of hematopoietic repopulating function are unknown. By using a member of the vertebrate Wnt family, Wnt-5A, the proliferation and differentiation of progenitors cocultured on stromal cells transduced with Wnt-5A or treated with Wnt-5A conditioned medium (CM) was unaffected. However, i.p. injection of Wnt-5A CM into mice engrafted with human repopulating cells increased multilineage reconstitution by >3-fold compared with controls. Furthermore, in vivo treatment of human repopulating cells with Wnt-5A CM produced a greater proportion of phenotypically primitive hematopoietic progeny that could be isolated and shown to possess enhanced progenitor function independent of continued Wnt-5A treatment. Our study demonstrates that Wnt-5A augments primitive hematopoietic development in vivo and represents an in vivo regulator of hematopoietic stem cell function in the human. Based on these findings, we suggest a potential role for activation of Wnt signaling in managing patients exhibiting poor hematopoietic recovery shortly after stem cell transplantation.
Gene Therapy | 1997
Barbara Murdoch; Daniel S. Pereira; Wu X; John E. Dick; Ellis J
We have developed a viral RNA (vRNA) dot blot assay for rapid identification of high-titer retrovirus vector production by packaging cell clones. The procedure employs Trizol LS reagent to purify vRNA from packaging cell supernatants, a sensitive dot blot assay, and PhosphorImager technology to quantify packaged viral genomes in 2 days. Experiments performed on viral supernatants of known biological titer demonstrated that the vRNA dot blot assay was extremely sensitive and that dot intensity correlated directly with viral titer. It is often necessary to analyze approximately 100 virus producing cell clones, making this method useful as a rapid screen to identify the highest virus producing clones. The vRNA dot blot assay consistently identified a subset of candidate high-titer producer cell clones. In three independent screens the supernatant with the highest biological titer was produced by one of the previously defined candidate high-titer producer clones. Our procedure greatly facilitates virus titration by: (1) rapidly eliminating the vast majority of low-titer producer cell clones; (2) accurately identifying the subset of candidate high-titer producer clones for further biological titration and assessment of the proviral genomic structure; and (3) reducing laborious tissue culture manipulations to a minimum. Furthermore, the reliance of this method on molecular detection makes it ideally suited for the isolation of high-titer clones lacking a drug selection marker.
Nature | 1994
Tsvee Lapidot; Sirard C; Josef Vormoor; Barbara Murdoch; Trang Hoang; Julio R. Cáceres-Cortés; Mark D. Minden; Bruce Paterson; Michael A. Caligiuri; John E. Dick
Nature Medicine | 1996
Andre Larochelle; Josef Vormoor; Helmut Hanenberg; Jean C.Y. Wang; Mickie Bhatia; Tsvee Lapidot; Thomas Moritz; Barbara Murdoch; Xiang Li Xiao; Ikunoshin Kato; David A. Williams; John E. Dick
Science | 1992
Tsvee Lapidot; Françoise Pflumio; Monica Doedens; Barbara Murdoch; Williams De; John E. Dick
Journal of Experimental Medicine | 2000
Frances N. Karanu; Barbara Murdoch; Lisa Gallacher; Dongmei M. Wu; Masahide Koremoto; Seiji Sakano; Mickie Bhatia
Journal of Experimental Medicine | 1997
Mickie Bhatia; Dominique Bonnet; Ursula Kapp; Jean C.Y. Wang; Barbara Murdoch; John E. Dick
Journal of Experimental Medicine | 1999
Mickie Bhatia; Dominique Bonnet; Dongmei Wu; Barbara Murdoch; Jeff Wrana; Lisa Gallacher; John E. Dick
Blood | 2000
Lisa Gallacher; Barbara Murdoch; Dongmei M. Wu; Francis Karanu; Mike Keeney; Mickie Bhatia